Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Aura biosciences announced the first Choroidal Melanoma patient has been dosed in the global phase 3 trial. Aura Biosciences has hope this trial will move forward and ultimately be approved as a first-line vision preserving treatment for Choroidal Melanoma patients. The CoMpass trial design has written agreement from the FDA under Special Protocol Assessment.